Rapigen, a South Korea-based developer and manufacturer of rapid diagnostic tests (RDTs), announced that the sixth and final shipment of 18 million malaria RDTs supplied under a national tender from the Ethiopian Ministry of Health (MOH-EPSS) is scheduled for dispatch via chartered cargo flight on August 7, 2025.
This marks the conclusion of a large-scale supply operation that began on July 7, consisting of six separate shipments—all of which have been delivered on schedule and without any incident. The operation demonstrates Rapigen’s proven capabilities in production, quality assurance, and international logistics.
Following a successful tender in 2024, this is Rapigen’s second consecutive year of delivering malaria RDTs to the Ethiopian government with no reported delivery issues, achieving full contract compliance. Rapigen has also built ongoing partnerships with leading global health organizations such as the WHO, UNDP, and the Global Fund, contributing actively to malaria control efforts throughout Africa.
The RDTs supplied to Ethiopia are second-generation malaria tests, specifically designed to detect HRP2 gene deletion variants, which have emerged as a diagnostic challenge in certain African regions. Unlike conventional HRP2-only tests, Rapigen’s kits provide reliable detection of these variants, making them increasingly trusted by frontline healthcare professionals.
In addition, Rapigen has completed the development of a third-generation malaria RDT, featuring combined detection of HRP2 and pLDH antigens in a single line to improve usability, sensitivity, and coverage across multiple malaria strains. This new product is currently undergoing regulatory registration in several African countries and is expected to support field-level diagnostic accuracy and national malaria elimination programs.
Ahead of the final shipment, Rapigen staff from production, logistics, and quality departments gathered at the export site for a commemorative photo, marking the successful execution of the project. This moment serves to highlight Rapigen’s commitment to reliable supply and global public procurement excellence.
A Rapigen representative stated, “This partnership with the Ethiopian government not only showcases our technological capabilities, but also proves our ability to execute timely and accurate deliveries. We remain committed to working with governments and international agencies to support malaria elimination across Africa.”
Rapigen will continue expanding its global partnerships through field-ready diagnostic technologies tailored to the needs of public health systems across the African continent.
Media Contact
Company Name: Rapigen
Contact Person: Jung Soo-yeon (marketing manager)
Email: Send Email
Country: South Korea
Website: https://www.rapigen.com
